Recent progress in small molecule CCR5 antagonists as potential HIV-1 entry inhibitors

Current Pharmaceutical Design

Volumn 18, Issue 1, 2012, Pages 100-112

  Chen, Wenwen ^a   Zhan, Peng ^a   de Clercq, Erik ^b   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

AIDS; Binding mode; CCR5; Coreceptor; Entry; HIV; HTS; Small molecule antagonist

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; AK 317; AK 530; ANTIVIRUS AGENT; APLAVIROC; CENICRIVIROC; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PF 232798; PIPERIDINE DERIVATIVE; PROTEINASE INHIBITOR; PYRIDIN 2 YLOXYMETHYLPIPERIDIN 1 YLBUTYL AMIDE DERIVATIVE; QUINOLINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SCH 532706; UNCLASSIFIED DRUG; USAMBARENSINE;

ANTIVIRAL ACTIVITY; BINDING AFFINITY; CHEMICAL STRUCTURE; CYTOTOXICITY; DRUG BIOAVAILABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; RECEPTORS, CCR5; VIRUS INTERNALIZATION;

EID: 84862910447     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212798919084     Document Type: Review

References (77)

1. UNAIDS Report on the Global AIDS Epidemic 2010. http://www.unaids.org/en/.
2. Mehellou Y, De Clercq E. Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go? J Med Chem 2010; 53: 521-38.
3. Murphy EL, Collier AC, Kalish LA, et al. Viral Activation Transfusion Study Investigators. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17-26.
4. Introcaso CE, Hines JM, Kovarik CL. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors. J Am Acad Dermatol 2010; 63: 549-61.
5. Introcaso CE, Hines JM, Kovarik CL. Cutaneous toxicities of antiretroviral therapy for HIV: part II. Nonnucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome. J Am Acad Dermatol 2010; 63: 563-9.
6. Werb D, Mills EJ, Montaner JS, Wood E. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis. Lancet Infect Dis 2010; 10: 464-9.
7. Cooley LA, Lewin SR. HIV-1 cell entry and advances in viral entry inhibitor therapy. J Clin Virol 2003; 26: 121-32.
8. Nowak SA, Chou T. Mechanisms of receptor/coreceptor-mediated entry of enveloped viruses. Biophys J 2009; 96: 2624-36.
9. De Clercq E. New anti-HIV agents and targets. Med Res Rev 2002; 22: 531-65.
10. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
11. Wu Y, Yoder A. Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog 2009; 5: e1000520. doi: 10.1371/journal.ppat. 1000520.
12. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21: 265-304.
13. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-77.
14. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-5.
15. Ferain T, Hoveyda H, Ooms F, Schols D, Bernard J, Fraser G. Agonist-Induced Internalization of CC Chemokine Receptor 5 as a Mechanism to Inhibit HIV Replication. J Pharmacol Exp Ther 2011; 337(3): 655-62.
16. Cormier EG, Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol 2002; 76: 8953-7.
17. Fano A, Ritchie DW, Carrieri A. Modeling the structural basis of human CCR5 chemokine receptor function: from homology model building and molecular dynamics validation to agonist and antagonist docking. J Chem Inf Model 2006; 46: 1223-35.
18. Maeda K, Das D, Ogata-Aoki H, et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 2006; 281: 12688-98.
19. Biswas P, Tambussi G, Lazzarin A. Access denied? The status of co-receptor inhibition to counter HIV entry. Expert Opin Pharmacother 2007; 8: 923-33.
20. Thoma G, Nuninger F, Schaefer M, et al. Orally bioavailable competitive CCR5 antagonists. J Med Chem 2004; 47: 1939-55.
21. Palani A, Tagat JR. Discovery and development of small molecule chemokine coreceptor CCR5 antagonists. J Med Chem 2006; 49: 2851-7.
22. Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT. An update in the development of HIV entry inhibitors. Curr Top Med Chem 2007; 7: 1273-89.
23. Qian KD, Morris-Natschke SL, Lee KH. HIV entry inhibitors and their pot-ential in HIV therapy. Med Res Rev 2009; 29: 369-93.
24. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-32.
25. Imamura S, Ichikawa T, Nishikawa Y, et al. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity. J Med Chem 2006; 49: 2784-93.
26. Takashima K, Miyake H, Kanzaki N, et al. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob. Agents Chemother 2005; 49: 3474-82.
27. Tremblay CL, Giguel F, Guan Y, Chou TC, Takashima K, Hirsch MS. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro. Antimicrob Agents Chemother 2005; 49: 3483-5.
28. Tobira Therapeutics Inc. Pipeline: Discovery and Development. http://www.Tobiratherapeutics. com/discovery.php
29. Long YQ, Feng DZ, Chen L, Chen RH. 1-(3-Amino-propyl)-piperidin-4-yl-amides, pharmaceutical compositions, processes for their preparation and uses. W.O. Patent 09,052,708, April 30, 2009.
30. Fan X, Zhang HS, Chen L, Long YQ. Efficient synthesis and identification of novel propane-1,3-diamino bridged CCR5 antagonists with variation on the basic center carrier. Eur J Med Chem 2010; 45: 2827-40.
31. Stupple PA, Batchelor DV, Corless M, et al. An Imidazopiperidine Series of CCR5 Antagonists for the Treatment of HIV: The Discovery of N-{(1S)-1-(3-Fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem 2011; 54: 67-77.
32. Ernst J, Dahl R, Lum C, et al. Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists. Bioorg Med Chem Lett 2008; 18: 1498-501.
33. Barber CG, Blakemore DC, Chiva JY, Eastwood RL, Middleton DS, Paradowski KA. 1-Amido-1-phenyl-3-piperidinylbutanes-CCR5 antagonists for the treatment of HIV. Part 1. Bioorg Med Chem Lett 2009, 19: 1075-9.
34. Barber CG, Blakemore DC, Chiva JY, Eastwood, RL, Middleton DS, Paradowski KA. 1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2. Bioorg Med Chem Lett 2009 19: 1499-503.
35. Kazmierski WM, Aquino C, Chauder BA, et al. Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1. J Med Chem 2008, 51: 6538-46.
36. Duan M, Aquino C, Ferris R, et al. [2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring. Bioorg Med Chem Lett 2009; 19: 1610-3.
37. Kazmierski WM, Anderson DL, Aquino C, et al. Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile. J Med Chem 2011; 54: 3756-67.
38. Duan M, Aquino C, Dorsey GF Jr, Ferris R, Kazmierski WM. 4,4-Disubstituted cyclohexylamine based CCR5 chemokine receptor antagonists as anti-HIV-1 agents. Bioorg Med Chem Lett 2009; 19: 4988-92.
39. Duan M, Peckham J, Edelstein M, et al. Discovery of N-benzyl-N'-(4-pipyridinyl) urea CCR5 antagonists as anti-HIV-1 agents (I): optimization of the amine portion. Bioorg Med Chem Lett 2010; 20: 7397-400.
40. Duan M, Peckham J, Edelstein M, et al. Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (II): modification of the acyl portion. Bioorg Med Chem Lett 2010; 20: 7401-4.
41. Maeda K, Nakata H, Koh Y, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 2004; 78: 8654-62.
42. Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008; 52: 858-65.
43. Maeda K, Das D, Yin PD, et al. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. J Mol Biol 2008; 381: 956-74.
44. Rotstein DM, Gabriel SD, Makra F, et al. Spiropiperidine CCR5 antagonists. Bioorg Med Chem Lett 2009; 19: 5401-6.
45. Gabriel SD, Rotstein DM. Heterocycle antiviral compounds. U.S. Patent 2,005,176,703, August 11, 2005.
46. Yang H, Lin X. F, Padilla F, et al. Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist. Bioorg Med Chem Lett 2009; 19: 209-13.
47. Rotstein DM, Yang HB. Heterocyclic antiviral compounds. W.O. Patent 09,135,788, November 12, 2009.
48. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci 1999; 96: 5698-703.
49. Shiraishi M, Aramaki Y, Seto M, et al. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem 2000; 43: 2049-63.
50. Liu T, Weng Z, Dong X, Hu Y. Recent advances in the development of small-molecule CCR5 inhibitors for HIV. Mini Rev Med Chem 2010; 10: 1277-92.
51. Tobira Therapeutics Inc. Receives US Patent for TBR-652: Clinical trial currently in Phase I. http://www.tobiratherapeutics.com/ 8_18_08.php
52. Seto M, Aikawa K, Miyamoto N, et al. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. J Med Chem 2006; 49: 2037-48.
53. Palani A, Shapiro S, Clader JW, et al. Discovery of 4-[(Z)-(4-bromophenyl)-(ethoxyimino)methyl]-1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl-1,4'-bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J Med Chem 2001; 44: 3339-42.
54. Tagat JR, McCombie SW, Nazareno D, et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem 2004; 47: 2405-8.
55. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49: 4911-9.
56. Merck Reports Initial Results of Phase III Studies with Vicriviroc in Treatment-Experienced HIV-Infected Patients. https://merck.com/newsroom/news-release-archive/research-anddevelopment/ 2010_0217.html
57. Xue CB, Cao GF, Huang TS, et al. Piperizinylpiperidine derivatives as chemokine receptor antagonists. W.O. Patent 2,005,101,838, October 27, 2005.
58. CCR5 ANTAGONIST PROGRAM. Orally-Administered Therapeutics for HIV Infection. http://www.incyte.com/backgrounders% 208.10.06/CCR5%20Backgrounde r.sept.pdf
59. Lemoine RC, Wanner J. Small molecule antagonists of the chemokine receptor CCR5. Curr Top Med Chem 2010; 10: 1299-338.
60. Thoma G, Beerli C, Bigaud M, et al. Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo. Bioorg Med Chem Lett 2008; 18: 2000-5.
61. Deems GS, Remy L, Mark RD, Jutta W. Heterocyclic antiviral compounds. W.O. Patent 09,013,171, January 29, 2009.
62. Bourque E, Metz M, Barrd IR, Bridger G, Skerlj RT. Chemokine receptor binding compounds. W.O. Patent 08,070,758, June 12, 2008.
63. Lemoine RC, Petersen AC, Setti L, et al. Evaluation of secondary amide replacements in a series of CCR5 antagonists as a means to increase intrinsic membrane permeability. Part 1: Optimization of gem-disubstituted azacycles. Bioorg Med Chem Lett 2010; 20: 704-8.
64. Wanner J, Chen L, Lemoine RC, et al. Evaluation of amide replacements in CCR5 antagonists as a means to increase intrinsic permeability. Part 2: SAR optimization and pharmacokinetic profile of a homologous azacyle series. Bioorg Med Chem Lett 2010; 20: 6802-7.
65. Rotstein DM, Melville CR, Padilla F, et al. Novel hexahydropyrrolo
66. Tallant MD, Duan M, Freeman GA, et al. Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1. Bioorg Med Chem Lett 2011; 21: 1394-8.
67. Wei RG, Arnaiz DO, Chou YL, et al. CCR5 receptor antagonists: discovery and SAR study of guanylhydrazone derivatives. Bioorg Med Chem Lett 2007; 17: 231-4.
68. Lu SF, Chen B, Davey D, et al. CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives. Bioorg Med Chem Lett 2007; 17: 1883-7.
69. Wei RG, Chen B, Dunning L, et al. In: Discovery of potent and orally bioavailable CCR5 antagonists: Part I. Presented at the 233rd ACS National Meeting, abstract MEDI-066, Chicago, IL, USA, March 25-29, 2006.
70. Kim D, Wang L, Hale JJ, et al. Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties. Bioorg Med Chem Lett 2005; 15: 2129-34.
71. Skerlj R, Bridger G, Zhou Y, et al. Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. Bioorg Med Chem Lett 2011; 21: 2450-5.
72. Pett SL, Emery S, MacRae K, et al. In: Safety and activity of SCH532706, a small molecule chemokine receptor 5 antagonist in HIV-1-infected individuals. Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston. Abstract 38, 2008.
73. Pett SL, McCarthy MC, Cooper DA, et al. A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients. Antivir Ther 2009; 14: 111-5.
74. Pett SL, Zaunders J, Bailey M, et al. A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection. AIDS Res Hum Retroviruses 2010; 26: 653-61.
75. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008; 73: 789-800.
76. Wang T, Duan Y. Binding modes of CCR5-targetting HIV entry inhibitors: partial and full antagonists. J Mol Graph Model 2008; 26: 1287-95.
77. Shahlaei M, Madadkar-Sobhani A, Mahnam K, Fassihi A, Saghaie L, Mansourian M. Homology modeling of human CCR5 and analysis of its binding properties through molecular docking and molecular dynamics simulation. Biochim Biophys Acta 2011; 1808: 802-17.